Beta-2- adrenergic agonists agonists are used in the treatment of reversible airway disease. β-blockers, due to their bronchoconstrictor effects, are supposed to be deleterious in such patients. In this review, we are putting forth some recent studies and meta analysis, which indicate that the chronic use of β-blockers in patients with reversible airway disease does not produce pulmonary impairment. Also, these drugs need not be withheld from patients with other diseases like hypertension, after weighing the risk: benefit ratio.
|Number of pages||4|
|Journal||Journal of Clinical and Diagnostic Research|
|Publication status||Published - 06-05-2011|
All Science Journal Classification (ASJC) codes
- Clinical Biochemistry